| Literature DB >> 29094177 |
Sun H Park1, Evan T Keller2, Yusuke Shiozawa3.
Abstract
Bone is the most common site of prostate cancer metastasis. Once prostate cancer cells metastasize to bone, the mortality rate of prostate cancer patients increases significantly. Furthermore, bone metastases produce multiple skeletal complications, including bone pain that impairs the patients' quality of life. Effective therapies for bone metastatic disease are underdeveloped with most current therapies being primarily palliative with modest survival benefit. Although the exact mechanisms through which prostate cancer metastasizes to bone are unclear, growing evidence suggests that the bone marrow microenvironment, particularly its hematopoietic activity, is a significant mediator of prostate cancer bone tropism. Moreover, the bone microenvironment may regulate metastatic prostate cancer cells between dormant and proliferative states. In this review, we discuss (1) how prostate cancer cells interact with the bone microenvironment to establish bone metastases and (2) current and future potential treatments for prostate cancer patients with bone metastases.Entities:
Keywords: Bone marrow microenvironment; Bone metastasis; Bone-targeted therapy; Prostate cancer; Skeletal complications
Mesh:
Year: 2017 PMID: 29094177 PMCID: PMC5807175 DOI: 10.1007/s00223-017-0350-8
Source DB: PubMed Journal: Calcif Tissue Int ISSN: 0171-967X Impact factor: 4.333